Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Rozlytrek (entrectinib) inhibits the activity of TrkA/B/C, Ros1 fusion proteins, and Alk, which leads to induction of apoptosis and inhibition of proliferation in cells expressing these kinases (PMID: 27003761). Rozlytrek (entrectinib) is FDA approved for use in patients with ROS1 positive non-small cell lung cancer and in adult and pediatric (12 years and older) patients with solid tumors harboring NTRK fusions without known acquired resistance mutations (FDA.gov).
|DrugClasses||ALK Inhibitor 25 ROS1 Inhibitor 15 Trk Receptor Inhibitor (Pan) 25|
|CAS Registry Number||1108743-60-7|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Entrectinib + Goserelin||Entrectinib Goserelin||0||1|
|Entrectinib + Letrozole||Entrectinib Letrozole||0||1|
|Entrectinib + PAC-1||Entrectinib PAC-1||0||1|
|Entrectinib + Selumetinib||Entrectinib Selumetinib||0||0|